Supplementary Figures S1-6 from Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

Supplementary Figures S1-6. Supplementary Fig. S1. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA mutations in different hotspots. Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S2. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the entire study population (n=729). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S3. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the luminal subgroup (n=376). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S4. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the HER2-positive patients who did not receive trastuzumab treatment (n=181). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S5. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in the HER2-positive patients who received trastuzumab treatment (n=41). Disease-free survival (Panel A); Distant disease-free survival (Panel B). Supplementary Fig. S6. Kaplan-Meier estimates of disease-free survival and distant disease-free survival according to the PIK3CA status in TN subgroup (n=128). Disease-free survival (Panel A); Distant disease-free survival (Panel B).